全文获取类型
收费全文 | 42630篇 |
免费 | 5911篇 |
国内免费 | 1073篇 |
专业分类
耳鼻咽喉 | 146篇 |
儿科学 | 526篇 |
妇产科学 | 462篇 |
基础医学 | 4641篇 |
口腔科学 | 682篇 |
临床医学 | 3637篇 |
内科学 | 1852篇 |
皮肤病学 | 432篇 |
神经病学 | 969篇 |
特种医学 | 1979篇 |
外国民族医学 | 76篇 |
外科学 | 5386篇 |
综合类 | 5739篇 |
现状与发展 | 7篇 |
一般理论 | 1篇 |
预防医学 | 1745篇 |
眼科学 | 137篇 |
药学 | 2455篇 |
33篇 | |
中国医学 | 842篇 |
肿瘤学 | 17867篇 |
出版年
2024年 | 65篇 |
2023年 | 671篇 |
2022年 | 994篇 |
2021年 | 2134篇 |
2020年 | 2011篇 |
2019年 | 1766篇 |
2018年 | 1648篇 |
2017年 | 1751篇 |
2016年 | 1929篇 |
2015年 | 2242篇 |
2014年 | 2944篇 |
2013年 | 3110篇 |
2012年 | 2449篇 |
2011年 | 2603篇 |
2010年 | 1980篇 |
2009年 | 1842篇 |
2008年 | 1878篇 |
2007年 | 1963篇 |
2006年 | 1951篇 |
2005年 | 1744篇 |
2004年 | 1450篇 |
2003年 | 1409篇 |
2002年 | 1145篇 |
2001年 | 1044篇 |
2000年 | 816篇 |
1999年 | 733篇 |
1998年 | 602篇 |
1997年 | 576篇 |
1996年 | 415篇 |
1995年 | 431篇 |
1994年 | 323篇 |
1993年 | 286篇 |
1992年 | 249篇 |
1991年 | 248篇 |
1990年 | 184篇 |
1989年 | 180篇 |
1988年 | 162篇 |
1987年 | 146篇 |
1986年 | 136篇 |
1985年 | 203篇 |
1984年 | 189篇 |
1983年 | 126篇 |
1982年 | 154篇 |
1981年 | 149篇 |
1980年 | 126篇 |
1979年 | 95篇 |
1978年 | 79篇 |
1977年 | 70篇 |
1976年 | 78篇 |
1973年 | 42篇 |
排序方式: 共有10000条查询结果,搜索用时 234 毫秒
1.
《Cancer radiothérapie》2022,26(4):611-615
In order to provide more convenient irradiation regimens for patient comfort, radiation facility organization and health expenses, new hypofractionated protocols have been evaluated. Moderately (dose/fraction: 2.3 to 3 Gy), then ultra (dose/fraction: 5.2 to 6.1 Gy) hypofractionated irradiations were first validated. The current question is: is it possible to go forward using extreme hypofractionated regimens (EHR) based on 1 to 3 fractions. Different irradiation techniques are under investigation. However, brachytherapy remains the smartest way to deliver a high dose in a small volume. We report prospective and retrospective study results which evaluated EHR for breast and prostate brachytherapy. While oncological outcome and toxicity profile appear extremely encouraging for low-risk breast cancer after a 1 to 4 fractions (6.25 to 20 Gy/fraction), the use of a single fraction of 19 to 23 Gy appears debatable for prostate cancer. Brachytherapy represents an emblematic example of EHR but longer follow-up and more mature results are awaited in order to specify the right indications and refine the EQD2 calculation method including new biological and technical factors. 相似文献
2.
3.
4.
5.
目的 临床观察白花蛇舌草干预湿热瘀滞型肠内多发息肉患者内镜治疗术后复发情况。方法 采用前瞻性的随机空白对照试验设计,选取2019年9月1日—2020年12月31日上海中医药大学附属普陀医院消化科收治的门诊及住院结直肠多发息肉患者132例作为研究对象。采用随机方法分为对照组和试验组,每组66例。对照组行内镜治疗术给予常规治疗后无药物干预,试验组在对照基础上给予白花蛇舌草汤剂(每日取白花蛇舌草15 g、大枣3枚,煎取400 mL汤剂,分2次饭后温服)治疗,连续干预1年。观察并比较两组术前与术后1年肠道内息肉的复发率、息肉数目、息肉最大直径、中医证候评分及肝肾功能及血常规的差异。结果 干预1年后,试验组复发9例(14.75%),对照组复发21例(33.33%),两组息肉复发率比较,差异有统计学意义(P<0.05)。试验组腺瘤、伴重度异型增生、体质量指数(BMI)≥24 kg·m-2患者治疗后息肉复发率均较对照组同类型降低,差异显著(P<0.05);术后1年试验组息肉最大直径及息肉数目均较对照组显著减小,差异显著(P<0.05);术后1年试验组中医证候各项评分均显著低于对照组(P<0.05);术后1年,两组中医证候疗效比较,差异具有统计学意义(P<0.05),且术前、术后1年两组患者肝肾功能、凝血功能等安全性指标无显著差异。结论 应用白花蛇舌草干预结直肠息肉术后患者,1年后明显降低肠内息肉的复发率,尤以腺瘤性息肉、重度异型增生、BMI超重患者更显著,不仅改善临床症状,还能有效预防结直肠息肉的复发,改善患者的预后。 相似文献
6.
《Diagnostic Histopathology》2022,28(3):156-160
Breast core biopsies are a standard component of the triple approach that includes clinical examination, imaging and tissue sampling. Conventional cores, diagnostic vacuum assisted biopsy and vacuum assisted excisions are established methods for sampling and managing breast lesions. It is important to be aware of the potential pitfalls in the technical handling and interpretation of the limited core biopsy samples. Here, we present a clinically oriented, well illustrated overview of the common diagnostic pitfalls based on the author's diagnostic and second opinion practice, emphasize the value of clinicopathological correlation and provide histological tips and clues with useful immunohistochemistry to aid the reporting pathologists in their daily interpretation of breast core biopsies. 相似文献
7.
8.
9.
Marike Gabrielson Mattias Hammarström Magnus Bäcklund Jenny Bergqvist Kristina Lång Ann H Rosendahl Signe Borgquist Roxanna Hellgren Kamila Czene Per Hall 《International journal of cancer. Journal international du cancer》2023,152(11):2362-2372
Tamoxifen prevents recurrence of breast cancer and is suggested for preventive risk-reducing therapy. Tamoxifen reduces mammographic density, a proxy for therapy response, but little is known about its effects in remodelling normal breast tissue. Our study, a substudy within the double-blinded dose-determination trial KARISMA, investigated tamoxifen-specific changes in breast tissue composition and histological markers in healthy women. We included 83 healthy women randomised to 6 months daily intake of 20, 10, 5, 2.5, 1 mg of tamoxifen or placebo. The groups were combined to “no dose” (0-1 mg), “low-dose” (2.5-5 mg) or “high-dose” (10-20 mg) of tamoxifen. Ultrasound-guided biopsies were collected before and after tamoxifen exposure. In each biopsy, epithelial, stromal and adipose tissues was quantified, and expression of epithelial and stromal Ki67, oestrogen receptor (ER) and progesterone receptor (PR) analysed. Mammographic density using STRATUS was measured at baseline and end-of-tamoxifen-exposure. We found that different doses of tamoxifen reduced mammographic density and glandular-epithelial area in premenopausal women and associated with reduced epithelium and increased adipose tissue. High-dose tamoxifen also decreased epithelial ER and PR expressions in premenopausal women. Premenopausal women with the greatest reduction in proliferation also had the greatest epithelial reduction. In postmenopausal women, high-dose tamoxifen decreased the epithelial area with no measurable density decrease. Tamoxifen at both low and high doses influences breast tissue composition and expression of histological markers in the normal breast. Our findings connect epithelial proliferation with tissue remodelling in premenopausal women and provide novel insights to understanding biological mechanisms of primary prevention with tamoxifen. 相似文献
10.